CNS Pharmaceuticals Inc Ordinary Shares CNSP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CNSP is a good fit for your portfolio.
News
-
CNS Pharmaceuticals Announces Reverse Stock Split
-
CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
-
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
-
CNS Pharmaceuticals to Present at the LSX World Congress 2024
-
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
-
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
-
CNS Pharmaceuticals to Present at Two Investor Conferences in April
Trading Information
- Previous Close Price
- $3.13
- Day Range
- $3.08–3.85
- 52-Week Range
- $3.06–137.50
- Bid/Ask
- $3.52 / $3.70
- Market Cap
- $1.42 Mil
- Volume/Avg
- 106,691 / 27,875
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.cnspharma.com
Valuation
|
Metric
|
CNSP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNSP
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 0.26 |
Interest Coverage | −1,166.03 |
Quick Ratio
CNSP
Profitability
|
Metric
|
CNSP
|
|---|---|
Return on Assets (Normalized) | −422.98% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CNSP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Fqtmgfs | Thfkw | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Snhqmtl | Hjlrr | $111.3 Bil | |||
| Moderna Inc
MRNA
| Frcdrynr | Sxhxf | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Rdgtblfs | Scpc | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Blytphjz | Pdbrv | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ccbrsnzr | Qzrnf | $20.1 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mnjbzkns | Npyzsj | $16.1 Bil | |||
| Incyte Corp
INCY
| Kmylhggyy | Pnpprhs | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Kqpcptyjn | Rcdzbw | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Gqlywckcm | Nzdl | $12.2 Bil |